TY  - JOUR
AU  - Preis, Lukas
AU  - Villringer, Kersten
AU  - Brosseron, Frederic
AU  - Düzel, Emrah
AU  - Jessen, Frank
AU  - Petzold, Gabor C
AU  - Ramirez, Alfredo
AU  - Spottke, Annika
AU  - Fiebach, Jochen B
AU  - Peters, Oliver
TI  - Assessing blood-brain barrier dysfunction and its association with Alzheimer's pathology, cognitive impairment and neuroinflammation.
JO  - Alzheimer's research & therapy
VL  - 16
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2024-00934
SP  - 172
PY  - 2024
AB  - Blood-brain barrier (BBB) alterations may contribute to AD pathology through various mechanisms, including impaired amyloid-β (Aβ) clearance and neuroinflammation. Soluble platelet-derived growth factor receptor beta (sPDGFRβ) has emerged as a potential biomarker for BBB integrity. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) offers a direct assessment of BBB permeability. However, the relationship between BBB dysfunction, cognitive impairment, and AD pathology remains unclear, with inconsistent findings in the literature.We conducted a cross-sectional study using data from the DELCODE and DESCRIBE cohorts to investigate BBB dysfunction in participants with normal cognition (NC), mild cognitive impairment (MCI), and AD dementia. BBB function was assessed using DCE-MRI and sPDGFRβ levels in cerebrospinal fluid and AD biomarkers Aβ and tau were measured. In a subset of patients, the CSF/plasma-ratio of albumin (QAlb) as a standard marker of BBB integrity and markers of neuroinflammation were analyzed.91 participants (NC: 44, MCI: 21, AD: 26) were included in the analysis. The average age was 74.4 years, 42
KW  - Humans
KW  - Blood-Brain Barrier: pathology
KW  - Female
KW  - Cognitive Dysfunction: diagnostic imaging
KW  - Cognitive Dysfunction: pathology
KW  - Male
KW  - Aged
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: pathology
KW  - Cross-Sectional Studies
KW  - Magnetic Resonance Imaging
KW  - Neuroinflammatory Diseases: diagnostic imaging
KW  - Neuroinflammatory Diseases: pathology
KW  - Amyloid beta-Peptides: cerebrospinal fluid
KW  - Amyloid beta-Peptides: metabolism
KW  - Biomarkers: cerebrospinal fluid
KW  - Biomarkers: blood
KW  - Middle Aged
KW  - Aged, 80 and over
KW  - Receptor, Platelet-Derived Growth Factor beta: metabolism
KW  - tau Proteins: cerebrospinal fluid
KW  - tau Proteins: metabolism
KW  - Alzheimer’s disease (Other)
KW  - Alzheimer’s disease (Other)
KW  - Blood-brain barrier (Other)
KW  - DCE-MRI (Other)
KW  - Mild cognitive impairment (Other)
KW  - Pericyte (Other)
KW  - sPDGFRβ (Other)
KW  - Amyloid beta-Peptides (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Receptor, Platelet-Derived Growth Factor beta (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
KW  - sPDGFRβ (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39085945
C2  - pmc:PMC11290219
DO  - DOI:10.1186/s13195-024-01529-1
UR  - https://pub.dzne.de/record/271062
ER  -